期刊文献+

治疗性抗体的现状及发展趋势

暂未订购
导出
摘要 到2005年2月底,通过美国食品药物管理局(U.S.Food and Durug Administration,FDA)认证的治疗性抗体已达18种。从上世纪80年代至今,治疗性抗体的研究经历了高潮和低谷,现在又迎来了第二个春天。了解各类治疗性抗体的作用机制,把握住当前该类生药制品的发展趋势,才能把基础研究和制药产业紧密联系起来,开发出新药品。
出处 《国外医学(免疫学分册)》 2005年第5期308-312,共5页 Foreign Medical Sciences(Section of Immunology Foreign Medical Sciences)
基金 国家高科技发展计划项目973基金资助(2001CB510009)
关键词 治疗性抗体 FDA
  • 相关文献

参考文献19

  • 1Huston JS, George AJ. Engineered antibodies take center stage[ J]. Human Antibodies,2001,10(3-4): 127-142.
  • 2Reichert JM. Therapeutic monoclonal antibodies: trends in development and approval in the US[ J ]. Curr Opin Mol Ther ,2002,4(2 ): 110-118.
  • 3Hudson PJ,Souriau C.Engineered antibodies[J] .Nature Medicine,2003,9(1): 129-134.
  • 4Van De Putte LB, Atkins C, Malaise M, et alEfficacy and safety of adalimumab as monotherapy in patients with theumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed[J]. Ann Rheum Dis,2004,63(5) :508-516.
  • 5Clark M. Antibody humanization:a case of the "Emperor's new dothes"?[J]. Immunology Today,2000,21 (8) :397-402.
  • 6Caldas C, Coelho V, Kalil J, et al. Humanizaiton of the anti-CD18 antibody 6.7:an unexpected effect of a frameowrk residue in binding to antigen[ J ]. Molecular Immunology, 2003,39 (15): 941-952.
  • 7Padlan EA. A possible procedure for reducing the immunogenecity of antibody variable domains while preserving their ligand-binding properties[J] .Mole Immunol, 1991,28:489-498.
  • 8Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies[J]. Neurology,2003,61(9 Suppl 5):13-17.
  • 9McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains [ J ]. Nature, 1990, 348(6301) :552-554.
  • 10Ling MM. Large antibody display libraries for isolation of high-affinity antibodies[J]. Comb Chem High Throughput Screen,2003,6(5):421-432.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部